Literature DB >> 26361983

Dynamic susceptibility contrast MRI measures of relative cerebral blood volume continue to show promise as an early response marker in the setting of bevacizumab treatment.

Jerrold L Boxerman1, Kathleen M Schmainda1, Zheng Zhang1, Daniel P Barboriak1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26361983      PMCID： PMC4648309          DOI： 10.1093/neuonc/nov163

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  7 in total

1.  Predictive imaging marker of bevacizumab efficacy: perfusion MRI.

Authors:  Whitney B Pope
Journal:  Neuro Oncol       Date:  2015-04-24       Impact factor: 12.300

2.  MR contrast due to intravascular magnetic susceptibility perturbations.

Authors:  J L Boxerman; L M Hamberg; B R Rosen; R M Weisskoff
Journal:  Magn Reson Med       Date:  1995-10       Impact factor: 4.668

3.  Standardization of relative cerebral blood volume (rCBV) image maps for ease of both inter- and intrapatient comparisons.

Authors:  Devyani Bedekar; Todd Jensen; Kathleen M Schmainda
Journal:  Magn Reson Med       Date:  2010-09       Impact factor: 4.668

4.  Dynamic-susceptibility contrast agent MRI measures of relative cerebral blood volume predict response to bevacizumab in recurrent high-grade glioma.

Authors:  Kathleen M Schmainda; Melissa Prah; Jennifer Connelly; Scott D Rand; Raymond G Hoffman; Wade Mueller; Mark G Malkin
Journal:  Neuro Oncol       Date:  2014-01-15       Impact factor: 12.300

5.  Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trial.

Authors:  Kathleen M Schmainda; Zheng Zhang; Melissa Prah; Bradley S Snyder; Mark R Gilbert; A Gregory Sorensen; Daniel P Barboriak; Jerrold L Boxerman
Journal:  Neuro Oncol       Date:  2015-02-02       Impact factor: 12.300

6.  Relative cerebral blood volume is a potential predictive imaging biomarker of bevacizumab efficacy in recurrent glioblastoma.

Authors:  Philipp Kickingereder; Benedikt Wiestler; Sina Burth; Antje Wick; Martha Nowosielski; Sabine Heiland; Heinz-Peter Schlemmer; Wolfgang Wick; Martin Bendszus; Alexander Radbruch
Journal:  Neuro Oncol       Date:  2015-03-09       Impact factor: 12.300

7.  Repeatability of Cerebral Perfusion Using Dynamic Susceptibility Contrast MRI in Glioblastoma Patients.

Authors:  Kourosh Jafari-Khouzani; Kyrre E Emblem; Jayashree Kalpathy-Cramer; Atle Bjørnerud; Mark G Vangel; Elizabeth R Gerstner; Kathleen M Schmainda; Kamran Paynabar; Ona Wu; Patrick Y Wen; Tracy Batchelor; Bruce Rosen; Steven M Stufflebeam
Journal:  Transl Oncol       Date:  2015-06       Impact factor: 4.243
  7 in total
  3 in total

1.  Multiparametric MRI for early identification of therapeutic response in recurrent glioblastoma treated with immune checkpoint inhibitors.

Authors:  Joseph Song; Priyanka Kadaba; Amanda Kravitz; Adilia Hormigo; Joshua Friedman; Puneet Belani; Constantinos Hadjipanayis; Benjamin M Ellingson; Kambiz Nael
Journal:  Neuro Oncol       Date:  2020-11-26       Impact factor: 12.300

Review 2.  Imaging of intratumoral heterogeneity in high-grade glioma.

Authors:  Leland S Hu; Andrea Hawkins-Daarud; Lujia Wang; Jing Li; Kristin R Swanson
Journal:  Cancer Lett       Date:  2020-02-27       Impact factor: 8.679

Review 3.  Conventional and advanced magnetic resonance imaging in patients with high-grade glioma.

Authors:  Whitney B Pope; Garth Brandal
Journal:  Q J Nucl Med Mol Imaging       Date:  2018-04-26       Impact factor: 2.346
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.